Your browser is no longer supported. Please, upgrade your browser.
OTLK Outlook Therapeutics, Inc. weekly Stock Chart
OTLK [NASD]
Outlook Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.16 Insider Own4.20% Shs Outstand16.10M Perf Week175.23%
Market Cap48.30M Forward P/E- EPS next Y-2.05 Insider Trans- Shs Float14.41M Perf Month88.68%
Income-40.20M PEG- EPS next Q-0.41 Inst Own0.90% Short Float3.77% Perf Quarter-71.59%
Sales3.40M P/S14.21 EPS this Y27.00% Inst Trans-71.07% Short Ratio0.16 Perf Half Y-48.63%
Book/sh-2.68 P/B- EPS next Y- ROA-186.70% Target Price4.00 Perf Year-62.75%
Cash/sh0.01 P/C241.50 EPS next 5Y- ROE189.60% 52W Range0.85 - 10.96 Perf YTD-25.00%
Dividend- P/FCF- EPS past 5Y- ROI778.50% 52W High-72.63% Beta-
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low252.94% ATR0.32
Employees56 Current Ratio0.10 Sales Q/Q37.50% Oper. Margin- RSI (14)58.62 Volatility32.43% 14.37%
OptionableNo Debt/Eq- EPS Q/Q82.30% Profit Margin- Rel Volume19.53 Prev Close3.00
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume3.41M Price3.00
Recom2.00 SMA20113.75% SMA50-23.48% SMA200-49.61% Volume0 Change0.00%
May-16-19Initiated Oppenheimer Outperform $12
Apr-22-19Initiated Ascendiant Capital Markets Buy
May-20-19 09:02AM  Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days MarketWatch +42.86%
May-17-19 03:17PM  Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know Benzinga +37.25%
09:47AM  Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days MarketWatch
May-16-19 09:48AM  Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer MarketWatch +68.06%
May-15-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019 GlobeNewswire -11.62%
Apr-26-19 08:00AM  Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development GlobeNewswire +6.82%
Apr-10-19 09:00AM  Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire -45.08%
Apr-01-19 08:00AM  Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010 GlobeNewswire
Mar-15-19 09:00AM  Outlook Therapeutics Announces Reverse Stock Split GlobeNewswire
Mar-05-19 08:00AM  Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements GlobeNewswire -6.49%
Mar-01-19 08:00AM  Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA GlobeNewswire
Feb-14-19 08:00AM  Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019 GlobeNewswire +24.27%
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-01-19 09:15AM  Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement GlobeNewswire
Jan-22-19 09:00AM  Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants GlobeNewswire
Jan-02-19 09:15AM  Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement GlobeNewswire +10.00%
Dec-18-18 09:00AM  Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 GlobeNewswire +14.29%
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.